PATENT CLAIM ANALYSIS

Application Number: 15920197
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["424", "139100"]

Abstract:
The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.

Claim (Index 31):
The isolated antibody, or antigen-binding fragment thereof, of  claim 24 , which competes with an antibody comprising the VH region set forth in SEQ ID NO: 1 and the VL region set forth in SEQ ID NO:2 for binding to CD40.

Metadata:
- Claim Count in Document: 19.0
- Percentile: 90.0
- Lexical Diversity: 1.09677
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14067770', '15594367', '14613110', '13458730', '14995741']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8104247805240665
- 35 USC 102 Novelty (BERT): 0.5901950839586344
- Combined Prediction Score: 0.7884018108675234
- Mean Citation Score: 493.76353200000005
- Max Citation Score: 520.31396
- Similarity Product: 458.1208518523312

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test